Edward Schutter - Establishment Labs Independent Director
| ESTA Stock | USD 49.69 1.42 2.94% |
Director
Mr. Edward James Schutter is Independent Director of the Company., since January 2016. He has over thirty years of pharmaceutical industry experience and has served as the President and Chief Executive Officer of Arbor Pharmaceuticals, Inc. since April 2010. Prior to joining Arbor Pharmaceuticals, Mr. Schutter served in various roles at Sciele Pharma, Inc., a subsidiary of Shionogi Co., Ltd., including as President and Chief Operating Officer from 2007 to 2009 and as Vice President of Global Business Development at Solvay S.A. in Basel, Switzerland from 2002 to 2006. He also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. Mr. Schutter began his pharmaceutical career with ReidProvident Laboratories, Inc., a small entrepreneurial pharmaceutical company based in Atlanta, Georgia. He currently serves on the board of Knight Therapeutics, Inc., Vensun Pharmaceuticals, Inc., a privately held company, Mercer University and Georgia Bio, a privately held company since 2016.
| Age | 65 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | Building B15 and 25, Alajuela, Costa Rica |
| Phone | 506 2434 2400 |
| Web | https://www.establishmentlabs.com |
Edward Schutter Latest Insider Activity
Tracking and analyzing the buying and selling activities of Edward Schutter against Establishment Labs stock is an integral part of due diligence when investing in Establishment Labs. Edward Schutter insider activity provides valuable insight into whether Establishment Labs is net buyers or sellers over its current business cycle. Note, Establishment Labs insiders must abide by specific rules, including filing SEC forms every time they buy or sell Establishment Labs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Edward Schutter over three months ago Acquisition by Edward Schutter of 724 shares of Establishment Labs subject to Rule 16b-3 | ||
Edward Schutter over six months ago Acquisition by Edward Schutter of 382 shares of Establishment Labs subject to Rule 16b-3 | ||
Edward Schutter over six months ago Acquisition by Edward Schutter of 273 shares of Establishment Labs subject to Rule 16b-3 | ||
Edward Schutter over a year ago Acquisition by Edward Schutter of 10000 shares of Establishment Labs subject to Rule 16b-3 |
Establishment Labs Management Efficiency
The company has return on total asset (ROA) of (0.1694) % which means that it has lost $0.1694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.3775) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.29. At present, Establishment Labs' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 4.9 M, whereas Total Assets are forecasted to decline to about 150.6 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Frank Corvino | HealthEquity | 68 | |
| Evelyn Dilsaver | HealthEquity | 62 | |
| Debra McCowan | HealthEquity | 46 | |
| Barbara Mowry | National Research Corp | 70 | |
| P Shastri | National Research Corp | 65 | |
| Kjersti Kanne | National Research Corp | N/A | |
| Ian Sacks | HealthEquity | 47 | |
| John Nunnelly | National Research Corp | 65 | |
| Michael Leavitt | HealthEquity | 66 | |
| Brita Eilertsen | National Research Corp | 53 | |
| William Stead | HealthStream | 69 | |
| Savita Acharya | National Research Corp | 41 | |
| Frank Gordon | HealthStream | 55 | |
| Manu Rana | HealthEquity | 45 | |
| Gayle Wellborn | HealthEquity | 56 | |
| Harald Arnet | National Research Corp | N/A | |
| Jeffrey McLaren | HealthStream | 51 | |
| Adrian Dillon | HealthEquity | 63 | |
| Martin Harris | HealthStream | 61 | |
| Dale Polley | HealthStream | 67 | |
| Martiny Harris | HealthStream | 59 | |
Management Performance
| Return On Equity | -15.38 | ||||
| Return On Asset | -0.17 |
Establishment Labs Leadership Team
Elected by the shareholders, the Establishment Labs' board of directors comprises two types of representatives: Establishment Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Establishment. The board's role is to monitor Establishment Labs' management team and ensure that shareholders' interests are well served. Establishment Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Establishment Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Hung, Independent Director | ||
| Lisa Gersh, Independent Director | ||
| Juan Quiros, CEO, Director | ||
| Heather Brennan, Head Operations | ||
| Nicholas Lewin, Independent Director | ||
| Roberto Mezerville, Chief Officer | ||
| Lisa Colleran, Independent Director | ||
| Paul Rodio, Chief Officer | ||
| Renee Gaeta, CFO | ||
| Dennis Condon, Independent Director | ||
| Salvador Santos, COO | ||
| Jeremy Livianu, General Counsel | ||
| Alberto Quesada, Vice President Quality & OUS Regulatory Affairs | ||
| Edward Schutter, Independent Director | ||
| Allan Weinstein, Independent Director | ||
| Ivan Bilic, Senior OUS | ||
| Eddie Oliveira, Vice President of Sales, Brazil | ||
| Ross Mansbach, General Officer | ||
| Jeffrey Bettinger, Global People | ||
| Neeta Toprani, Corporate Secretary | ||
| Rosalyn dIncelli, Medical Clinical | ||
| Rajbir Denhoy, Chief Officer | ||
| Salvador Dada, Chief Officer | ||
| Elizabeth Newman, VP Unit |
Establishment Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Establishment Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.38 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.48) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 1.47 B | ||||
| Shares Outstanding | 27.46 M | ||||
| Shares Owned By Insiders | 12.30 % | ||||
| Shares Owned By Institutions | 78.54 % | ||||
| Number Of Shares Shorted | 4.93 M | ||||
| Price To Earning | (20.11) X |
Pair Trading with Establishment Labs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Establishment Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Establishment Labs will appreciate offsetting losses from the drop in the long position's value.Moving against Establishment Stock
| 0.89 | SIBN | Si Bone Financial Report 6th of May 2024 | PairCorr |
| 0.87 | SRDX | SurModics Earnings Call This Week | PairCorr |
| 0.82 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.81 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
| 0.78 | DH | Definitive Healthcare Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Establishment Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Establishment Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Establishment Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Establishment Labs Holdings to buy it.
The correlation of Establishment Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Establishment Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Establishment Labs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Establishment Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Establishment Labs Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Establishment Stock analysis
When running Establishment Labs' price analysis, check to measure Establishment Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Establishment Labs is operating at the current time. Most of Establishment Labs' value examination focuses on studying past and present price action to predict the probability of Establishment Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Establishment Labs' price. Additionally, you may evaluate how the addition of Establishment Labs to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Establishment Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Establishment Labs. If investors know Establishment will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Establishment Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.07) | Revenue Per Share 6.451 | Quarterly Revenue Growth (0.28) | Return On Assets (0.17) | Return On Equity (15.38) |
The market value of Establishment Labs is measured differently than its book value, which is the value of Establishment that is recorded on the company's balance sheet. Investors also form their own opinion of Establishment Labs' value that differs from its market value or its book value, called intrinsic value, which is Establishment Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Establishment Labs' market value can be influenced by many factors that don't directly affect Establishment Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Establishment Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Establishment Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Establishment Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.